Diagnosing Lewy Body Disease: Clinical Criteria and Investigations
Diagnose dementia with Lewy bodies (DLB) using the 2017 revised consensus criteria, which require progressive dementia plus at least two core clinical features OR one core feature with at least one indicative biomarker for probable DLB. 1
Core Clinical Features to Identify
The four core clinical features that define DLB are 1:
- Cognitive fluctuations: Pronounced variations in attention and alertness, often occurring spontaneously
- Recurrent visual hallucinations: Typically well-formed and detailed, occurring spontaneously
- REM sleep behavior disorder (RBD): Dream enactment behavior that may precede cognitive decline by years (given increased diagnostic weighting in 2017 criteria) 2, 1
- Parkinsonism: Bradykinesia with rigidity, rest tremor, or postural instability (typically akineto-rigid without classical rest tremor) 3
Critical diagnostic timing rule: Diagnose DLB only when dementia occurs before or within 12 months of parkinsonism onset. If parkinsonism precedes dementia by more than 12 months, this is Parkinson disease dementia (PDD), not DLB 3.
Supportive Clinical Features
Look for these additional features that strengthen the diagnosis 1, 4:
- Severe neuroleptic sensitivity: Potentially life-threatening reactions to antipsychotic medications (a critical pitfall to avoid)
- Postural instability and falls
- Syncope or transient loss of consciousness
- Severe autonomic dysfunction: Constipation, orthostatic hypotension, urinary incontinence
- Hypersomnia and excessive daytime sleepiness
- Hyposmia: Reduced sense of smell
- Psychiatric symptoms: Delusions, anxiety, depression
- Cognitive profile: Prominent deficits in visuospatial ability and frontal executive function, with relative preservation of memory early in disease 3
Recommended Diagnostic Investigations
Indicative Biomarkers (High Diagnostic Value)
Order these tests to confirm probable DLB 1:
- Dopamine transporter SPECT imaging (DaTscan): Shows reduced basal ganglia uptake, distinguishing DLB from Alzheimer's disease
- ¹²³I-MIBG myocardial scintigraphy: Demonstrates reduced cardiac uptake (given increased diagnostic weighting in 2017 criteria) 2, 1
- Polysomnography: Confirms REM sleep without atonia, documenting RBD 5
Supportive Biomarkers
Consider these additional investigations 1:
- MRI brain without contrast: May show relative preservation of medial temporal lobe structures compared to Alzheimer's disease, though often normal early in disease 6
- FDG-PET: Shows occipital hypometabolism with relative preservation of posterior cingulate (cingulate island sign)
- EEG: May demonstrate prominent posterior slow-wave activity with periodic fluctuations
Emerging Biomarkers
α-Synuclein-specific biomarkers are in active development 2, 5:
- Skin biopsy for α-synuclein deposition
- CSF and plasma α-synuclein markers
- α-Synuclein PET imaging
Diagnostic Algorithm
For probable DLB: Dementia + (≥2 core features) OR (1 core feature + ≥1 indicative biomarker)
For possible DLB: Dementia + (1 core feature) OR (≥1 indicative biomarker)
Critical Pitfalls to Avoid
- Never prescribe typical or atypical antipsychotics without considering DLB, as severe neuroleptic sensitivity can be life-threatening 1
- Don't rely solely on structural imaging: MRI is often normal early in DLB and primarily helps exclude other pathology 6
- Recognize prodromal presentations: DLB may begin with psychiatric symptoms, sleep disturbances, or autonomic dysfunction before cognitive decline becomes apparent 7
- Assess during optimal cognitive states: Avoid diagnostic assessments during periods of fluctuation, which can lead to underestimation of cognitive abilities 8
Practical Diagnostic Approach
The 2017 revised criteria have high specificity but variable sensitivity 3. When clinical suspicion is high based on the characteristic constellation of cognitive fluctuations, visual hallucinations, and parkinsonism with early dementia, proceed directly to dopamine transporter imaging or MIBG scintigraphy to confirm the diagnosis rather than waiting for all features to manifest 1. Early diagnosis is crucial to implement appropriate management and avoid iatrogenic complications, particularly neuroleptic sensitivity 7.